Posters

    Systems Toxicology Approaches Enable Mechanistic Comparison Of Cigarette Smoke-Induced And Spontaneous Lung Tumors In The A/J Mouse Model

    Iskandar, A.; Xiang, Y.; Sewer, A.; Luettich, K.; Martin, F.; Talikka, M.; Schlage, W.; Vanscheeuwijck, P.; Veljkovic, E.; Gonzalez-Suarez, I.; Hoeng, J.; Peitsch, M.
    Conference date
    Jun 30, 2013
    Conference name

    International Congress of Toxicology (ICT) 2013
    Link to more information
    Topic
    Summary

    The A/J mouse strain is frequently utilized as an animal model for cigarette smoke (CS)-associated lung tumorigenesis. However, the high susceptibility of the strain to develop spontaneous lung tumors creates a challenge in understanding the mechanisms underlying the formation of lung tumors following CS exposure. This study demonstrates how systems toxicology approaches not only enable a better mechanistic understanding of CS-induced lung tumorigenesis in this model, but also allows for a clear distinction between smoke-induced and spontaneous tumors. Male A/J mice were exposed to whole-body mainstream CS (6 hours/day of 300 mg/m3 of total particulate matter, 5 days/week) for 18 months. An increased tumor incidence and multiplicity were observed in mice exposed to CS compared to an air exposed sham group. Transcriptomic analysis using Affymetrix Genechips® on 30 pairs of lung lesions (nodular hyperplasia, adenoma, and carcinoma combined) and surrounding, non-tumorous parenchyma samples for both exposed and sham animals identified 269 genes to be significantly differently expressed between the two groups (FDR<0.01).

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.